Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 9/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.54 |
| ▸ | MPL | P40238 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300430 | 0.84 | CYP1A2 (0.46) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL30122888 | 0.80 | HSD17B10 (0.62) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL3835119 | 0.80 | HSD17B10 (0.62) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12647588 | 0.79 | TYR (0.60) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12592156 | 0.79 | RAB9A (0.54) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL2517425 | 0.79 | MPL (0.67) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL13513647 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12592152 | 0.79 | HSD17B10 (0.67) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12592149 | 0.79 | MEN1 (0.65) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL14274836 | 0.79 | CYP1A2 (0.41) | ALDH1A1MEN1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390333-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-11-28 | — | — | US | disclosed |
| US-11974988-B2 | Neuroprotective compositions and methods of using the same | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-05-07 | — | — | US | disclosed |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-07-08 | — | — | US | disclosed |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-07-08 | — | — | US | disclosed |
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2078015-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1841750-B1 | HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-7968577-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| EP-1841750-A1 | HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7253283-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1708699-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- K .B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1703797-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006076509-A1 | HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154962-A1 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| WO-2005072729-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | ALDH1A1 3536/4885MEN1 4388/4885KMT2A 3366/4885 |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKBIA, NFKB1 | ALDH1A1 3536/4885MEN1 4388/4885KMT2A 3366/4885 |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | GAP43, NLN, SMN1; SMN2 | ALDH1A1 1731/4885MEN1 3116/4885KMT2A 3336/4885 |
| US-11974988-B2 | Neuroprotective compositions and methods of using the same | GAP43, NLN, SMN1; SMN2 | ALDH1A1 1731/4885MEN1 3116/4885KMT2A 3336/4885 |
| US-20060154962-A1 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB1, NFKB2 | ALDH1A1 3151/4885MEN1 4344/4885KMT2A 3641/4885 |
| US-20240390333-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | GAP43, NLN, SMN1; SMN2 | ALDH1A1 1731/4885MEN1 3116/4885KMT2A 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.